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Abstract
Background: The results of the latest epidemiological studies show that the problem of hyperuricemia 
affects many millions of people. The main purpose of the study was to assess the knowledge of physicians  
with regard to the epidemiology and treatment of hyperuricemia in Poland. 
Methods: CAPI (computer assisted personal interview) interviews were conducted using short ques-
tionnaires among primary health care physicians, cardiologists and diabetologists. The entire question-
naire included 11 questions. Questions were asked to physicians at 5 different periods in time. The 
number of physicians surveyed, depended on the time period, and ranged from 8663 to 9980.
Results: Only every 1 in 7 physicians (14%) considered that hyperuricemia in patients with cardio-
vascular risk factors begins when the uric acid level is 5 mg/dL, thus in line with the expert recom-
mendations. 72% of respondents asked to indicate the uric acid levels they consider to be indicative of 
hyperuricemia in patients in the cardiovascular risk group, gave values ranging from 6 to 7 mg/dL,  
namely the values justified in cases of a patient without such a risk, i.e. in the general population.  
86% of doctors surveyed gave values different from that recommended by experts.
Conclusions: The findings of the questionnaire in this survey suggests that doctors often underestimate 
the problem of hyperuricemia in patients with a high risk of cardiovascular disease. An important step 
towards more effective therapy of hyperuricemia in routine clinical practice is to raise the awareness of 
hyperuricemia and its comorbidities both among doctors and patients and encourage monitoring and 
treatment. (Cardiol J 2019; 26, 3: 241–252)
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Introduction
The results of recent epidemiological studies 
show that hyperuricemia affects many millions of 
people [1]. In the coming years, and in connection 
with an epidemic of obesity, metabolic disorders 
and an aging population among others factors, 
a further gradual increase in the incidence of hy-
peruricemia should be expected [2, 3].
Already on the basis of earlier studies, 
a conclusion was drawn that the relative risk of 
cardiovascular complications in patients, including 
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patients with hypertension, increases with a grow- 
ing level of uric acid in blood serum [4]. How-
ever, there was no evidence that hyperuricemia is 
a factor contributing to the development of cardio-
vascular disorders, because after considering the 
other risk factors in statistical analysis, the effect of 
hyperuricemia seemed to be insignificant [5]. In the 
recent years, there has been a revival of an inter-
est in uric acid as a prognostic and causative factor 
in cardiovascular disease (CVD). The analysis of 
large clinical trials on the relationship between 
hyperuricemia and the risk of cardiovascular com-
plications in hypertensive patients clearly points 
to uric acid as an independent predicative factor.
According to the Guidelines of the Polish 
Society of Arterial Hypertension in 2015, the 
determination of uric acid concentration is a basic 
test in patients with hypertension together with 
a morphology test, glycemia test, determination 
of sodium and potassium, lipid profile, creatinine, 
estimated glomerular filtration rate, albuminuria 
assessment and urinalysis [6]. Also, the latest 
2018 European Society of Cardiology/European 
Society of Hypertension (ESC/ESH) Guidelines for 
the management of arterial hypertension not only 
mentions the uric acid test as a basic test, but also 
considers it to be a factor affecting cardiovascular 
risk [7].
The definition of hyperuricemia varies widely 
between publications, which means that epide-
miological studies are inconsistent. However, 
based on the recent studies, analyses and recom-
mendations, physicians should seek to reach and 
maintain lifelong uric acid levels of < 6 mg/dL in 
the general population, and in patients with high 
cardiovascular risk, the target uric acid level of 
5 mg/dL should be considered [8]. According to 
the latest Expert Consensus on the diagnosis and 
treatment of patients with hyperuricemia and high 
cardiovascular risk, the target uric acid levels of 
< 5 mg/dL should be considered in patients with 
high cardiovascular risk, presenting at least two of 
the following risk factors: hypertension, diabetes, 
dyslipidemia, recent stroke or myocardial infarction 
and chronic kidney disease (CKD) [9].
The main purpose of the study was to assess the 
knowledge of physicians with regard to the epide-
miology and treatment of hyperuricemia in Poland. 
Research objectives were divided into three groups. 
The aim of the first group was to assess physician 
awareness with regard to the incidence of hyper-
uricemia, and in particular the frequency of ordering 
appropriate tests and application of therapeutic solu-
tions. The aim of the second group was to identify 
the actual risk of CVD and metabolic syndrome 
due to hyperuricemia according to primary health 
care physicians, cardiologists and diabetologists. An 
assessment of physician attitudes to the reference 
values of uric acid concentration levels, screening 
tests and hyperuricemia therapies available on the 
market, as well as  identification of treatment-related 
barriers was the goal of the third study group.
Methods
CAPI (computer assisted personal interview) 
interviews were conducted using short question-
naires among primary health care physicians, 
cardiologists and diabetologists. The entire ques-
tionnaire included 11 questions. Questions were 
asked to physicians at 5 different periods (Table 1). 
The number of physicians surveyed, depending 
on the time period, and ranged from 8663 to 9980. 
The doctors were asked the following questions:
 — Question 1. What concentration of uric acid do 
you consider to be hyperuricemia in patients 
at risk of cardiovascular disease?
 — Question 2. What diseases are, in your opinion, 
are most often accompanied by hyperuricemia?
 — Question 3. What is the average age of your 
patients with hyperuricemia > 5 mg/dL 
(298 μmol/L) in the cardiovascular risk group?
 — Question 4. How often do you order tests to 
measure uric acid concentration in blood serum 
for patients with hyperuricemia > 5 mg/dL 
(298 μmol/L) in the cardiovascular risk 
group?
 — Question 5. What is the average uric acid 
concentration of your hyperuricemia patients 
from the cardiovascular risk group?
Table 1. Questions at 5 periods in time with the following number of participating physicians.
1st period 2nd period 3rd period 4th period 5th period
Duration of  
the period
September –  
– November 2017
December 2017 – 
– January 2018
February – 
– March 2018
April – May  
2018
June  
2018
Number of surveyed  
physicians
9980 9740 9525 8663–9470 6910
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 — Question 6. At what concentration of uric acid 
in a patient at risk of cardiovascular disease 
do you administer pharmacological treatment 
of hyperuricemia?
 — Question 7. In what percentage of patients 
from the cardiovascular risk group (> 5 mg/ 
/dL, 298 μmol/L) taking medicines to reduce 
uric acid levels have you decreased the dose 
of the medicine in the last 3–4 months?
 — Question 8. In what percentage of patients 
from the cardiovascular risk group (> 5 mg/dl, 
298 μmol/L) taking medicines aimed to reduce 
uric acid levels have you increased the dose of 
the medicine in the last 3–4 months?
 — Question 9. In your opinion, how long should 
be the pharmacological treatment of hyper-
uricaemia last in patients with cardiovascular 
risk (> 5 mg/dL, 298 μmol/L)?
 — Question 10. From your observations, what are 
the effects on hyperuricemia on cardiovascular 
risk (> 5 mg/dL, 298 μmol/L)?
 — Question 11. Have you noticed an increase in 
the incidence of hyperuricemia in patients with 
cardiovascular risk (> 5 mg/dL, 298 μmol/L) 
over the past 2 years?
The study was performed over a period from 
September 2017 to June 2018. Questions were 
asked at 5 periods with the following number of 
participating physicians (Table 1).
Results
Only every 1 in 7 physicians (14%) considers 
that hyperuricemia in patients with cardiovascular 
risk factors begins when the uric acid level is 5 mg/ 
/dL, thus in line with the expert recommendations 
[8, 9]. 72% of respondents asked to indicate the uric 
acid levels they consider to be indicative of hyper-
uricemia in patients in the cardiovascular risk group 
gave values ranging from 6 to 7 mg/dL, namely the 
values justified in cases of patients without such 
a risk, i.e. in the general population. 86% of doctors 
surveyed gave values different from that recom-
mended by experts, namely other than 5 mg/dL, 
as the reference value of hyperuricemia in patients 
presenting with cardiovascular risk factors (Fig. 1).
In answer to the question of what diseases, 
according to them, most often accompany hy-
peruricemia, physicians indicated the most often 
hypertension (91%), metabolic syndrome (89%) 
and diabetes (84%) (Fig. 2).
According to the doctors surveyed, the aver-
age age of patients with hyperuricemia > 5 mg/dL 
(298 μmol/L) in the cardiovascular risk group was 
55 years. Nearly 1/3 doctors had declared that the 
average age of their patients with hyperuricemia 
> 5 mg/dL (298 μmol/L) in the cardiovascular risk 
group was 50 years or less, and the next one third 
of doctors indicated that the age was 60 years or 
more (Fig. 3).
Almost half of the doctors (48%) order a test 
of uric acid concentration in blood serum once 
a year in patients with hyperuricemia > 5 mg/dL 
(298 μmol/L) in the cardiovascular risk group, and 
more than 1/3 of physicians (38%) order the test 
twice a year (Fig. 4).
Average concentration levels of uric acid 
in patients with hyperuricemia > 5 mg/dL 
0.3%0.2%
14%
34%
39%
10%
2% 1% 0.3%
All respondents, 
n = 9980
Total
4 mg/dL
(238  
mmol/L)
5 mg/dL
(297 
mmol/L)
6 mg/dL
(356 
mmol/L)
7 mg/dL 
(416 
mmol/L)
8 mg/dL
(476 
mmol/L)
9 mg/dL
(535 
mmol/L)
10 mg/dL
(595 
mmol/L)
11 mg/dL
(654 
mmol/L)
12 mg/dL
(714 
mmol/L
What concentration of uric acid do you consider to be hyperuricemia in patients at risk of cardiovascular 
disease?
Figure 1. Uric acid reference concentration value considered by physicians as hyperuricaemia at the patients of 
cardiovascular risk group — distribution of all the responses.
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91% 89%
84%
24%
All respondents, 
n = 9980
Total
Arterial
hypertension
Metabolic
syndrome
Diabetes
mellitus
Others
What diseases are, in your opinion, are most often accompanied by hyperuricemia?
All respondents, 
n = 9740
Total Average age – 55.4 years
Up to 50 years From 51 to 59 years Over 60 years
Age
29%
36% 35%
What is the average age of your patients with hyperuricemia > 5 mg/dL (298 µmol/L) 
in the cardiovascular risk group?
All respondents, 
n = 9525
Total
7%
48%
38%
8%
Less than Three times a year
or moreonce a year
How often do you order tests to measure uric acid concentration in blood serum for patients 
with hyperuricemia > 5 mg/dL (298 µmol/L) in the cardiovascular risk group?
Once
a year
Twice
a year
Figure 2. Diseases usually accompanied by hyperuricaemia — distribution of responses.
Figure 3. Average age of patients with hyperuricaemia > 5 mg/dL (298 μmol/L) of the cardiovascular risk group — 
distribution of responses and average.
Figure 4. Frequency of ordering urea acid tests in serum at patients with hyperuricaemia > 5 mg/dL (298 μmol/L) of 
the cardiovascular risk group — distribution of responses.
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(298 μmol/L) in the cardiovascular risk group is 
higher among men than among women. It is on 
average 6.8 mg/dL in female patients and 7.4 mg/dL 
in male patients (Fig. 5).
The vast majority of doctors, namely 75% of 
respondents commence pharmacological treatment 
of hyperuricemia in a patient at risk of CVD, when 
the concentration of uric acid is between 6 and 
7 mg/dL, 14% — when this concentration is lower 
than 6 mg/dL, and another 11% — when it is above 
7 mg/dL (Fig. 6).
Physicians generally do not reduce the dose 
of medicine that lowers uric acid concentration in 
patients with hyperuricemia in the cardiovascular 
risk group. 72% of physicians had not reduced the 
dose of medicines in their patients in the prior 
3–4 months. The average percentage of patients 
with hyperuricemia in the cardiovascular risk 
group, from doctors who had reduced the dose of 
medicine which reduces uric acid concentration 
was 14% (taking into account only doctors had 
reduced dosage). Almost all doctors increased the 
doses of medicine reducing uric acid concentration 
in patients with hyperuricemia in the cardiovascu-
lar risk group — only 2% of physicians over the 
prior 3–4 months did not have this type of patient.
All respondents, 
n = 9525
Total
40%
21%
39%
34%
21%
45%
Women Men
> 7 mg/dL (416 mmol/L)
> 6 mg/dL (356 mmol/L)
£ 7 mg/dL (416 mmol/L) 
≥ 5 mg/dL (298 mmol/L) 
£ 6 mg/dL (356 mmol/L)
Average 6.8* 7.4*
What is the average uric acid concentration of your hyperuricemia patients from the 
cardiovascular risk group?
*Average tested on unit range, 
i.e. one could not choose 5.5
All respondents, 
n = 9470
Total
14%
75%
11%
Less than 6 mg/dL
(356 mmol/L)
Over 6 mg/dL (356 mmol/L)
up to 7 mg/dL (416 mmol/L)
Over 7 mg/dL
(416 mmol/L)
*Average tested on unit range, 
i.e. one could not choose 5.5
Average* concentration 
– 6,5 mg/dL
At what concentration of uric acid in a patient at risk of cardiovascullar disease do you administer 
pharmacological treatment of hyperuricemia?
Figure 5. Average concentration of uric acid at patients with hyperuricemia > 5 mg/dL (298 μmol/L) of the cardiovas-
cular risk group — distribution of responses and average.
Figure 6. Uric acid concentration value at which the physician includes pharmacologic treatment of hyperuricemia for 
patients of the cardiovascular risk group — aggregated distribution of responses and average.
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The average percentage of patients with hy-
peruricemia in the cardiovascular risk group, in 
cases of doctors who had increased the dose of 
drugs that lower medicines reducing uric acid con-
centration is 23% (includes only dose-increasing 
doctors) (Fig. 7).
90% of doctors believe that pharmacologi-
cal treatment of hyperuricemia in patients in the 
cardiovascular risk group should be included per-
manently (Fig. 8). 
Nearly 80% of respondents believe that hy-
peruricemia (> 5 mg/dL; 298 μmol/L) has a high 
impact on cardiovascular risk. The remaining 20% 
of doctors believed that the effect of hyperurice-
mia on cardiovascular risk is moderate (Fig. 9). 
Moreover, 91% doctors have observed an increase 
in the occurrence of hyperuricemia over the prior 
2 years in patients from the cardiovascular risk 
group (Fig. 10).
Discussion
Based on available research and recommenda-
tions, the target uric acid concentration of < 5 mg/dL 
All respondents, 
n = 8663
Total
2%
64%
28%
4% 2% 0%
0% (no such
patients)
1–20% 21–40% 41–60% 61–80% Over 80%
Average* percentage 
(physicians increasing the 
dose without 0% value) – 23%
In what percentage of patients from the cardiovascular risk group (> 5 mg/dl, 298 µmol/L) taking 
medicines aimed to reduce uric acid levels have you increased the dose of the medicine 
in the last 3–4 months?
*The average is tested on the step scale, 
e.g. you could not choose the value 5.5
All respondents, 
n = 8682
Total
4% 2% 4%
90%
1–2 years 3–4 years 5–10 years Chronic
In your opinion, how long should be the pharmacological treatment of hyperuricaemia last 
in patients with cardiovascular risk (> 5 mg/dL, 298 /L)?µmol
Figure 7. Percentage of patients with hyperuricemia > 5 mg/dL (298 μmol/L) in the cardiovascular risk group taking 
medicines lowering uric acid concentration, whose doctor had increased the dose in the prior 3–4 months — aggre-
gated distribution of responses and the average.
Figure 8. The assumed length of pharmacological treatment of hyperuricemia for patients in the cardiovascular risk 
group (> 5 mg/dL; 298 μmol/l) — distribution of responses.
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should be considered in patients with high cardio-
vascular risk. High cardiovascular risk patients 
are considered to be those persons with hyper-
tension, diabetes, metabolic syndrome, diagnosed 
atherosclerosis of any vascular bed (including 
patients with coronary artery disease [CAD] or 
atherosclerotic cerebrovascular disease) [8]. Ac-
cording to the position of international experts, 
the target uric acid concentration of < 5 mg/dL 
should be considered in patients with high car-
diovascular risk, presenting with at least two 
of the following factors: hypertension, diabetes, 
dyslipidaemia, recent stroke or myocardial infarc-
tion, CKD [9].
It should be noted that the PAMELA study 
confirmed the benefits of maintaining a level of 
approximately 5 mg/dL in patients with high car-
diovascular risk [10]. In the present study, patients 
were randomly recruited from the general popula-
tion and subjected to a detailed assessment of the 
cardiovascular risk profile. Echocardiography and 
blood pressure measurements were also performed 
other than at the doctor’s office. Data analysis sug-
gests the limit value of uric acid concentration of 
5.4 mg/dL, providing the best sensitivity ratio to 
the specificity of the study in predicting the risk 
of cardiovascular mortality and 4.9 mg/dL for total 
mortality.
All respondents, 
n = 6910 
Total
1%
20%
79%
Low Medium High
From your observations, what are the effects on hyperuricemia on cardiovascular risk 
(> 5 mg/dL, 298 µmol/L)?
Figure 9. Assessment of the impact of hyperuricemia (> 5 mg/dL, 298 μmol/L) on cardiovascular risk — distribution 
of responses.
Figure 10. Frequency of hyperuricemia for patients in the cardiovascular risk group (> 5 mg/dL; 298 μmol/L) within 
the prior 2 years — distribution of responses.
Have you noticed an increase in the incidence of hyperuricemia in patients with cardiovascular 
risk (> 5 mg/dL, 298 µmol/L) over the past 2 years?
All respondents, 
n = 6910 
Total
Yes – 91%
No – 9%
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The findings of the current study show that 
relatively few doctors are aware of the recommen-
dations related to the treatment of hyperuricemia 
in patients with high cardiovascular risk. Only 
14% of doctors (1 in 7 respondents) indicate the 
value recommended by experts, and 3/4 (72%) of 
respondents asked to indicate uric acid levels they 
considered to be hyperuricemia in patients from the 
cardiovascular risk group, indicate values ranging 
from 6 to 7 mg/dL, i.e. the value justified in patients 
without such a risk. Yet, it should not be surprising 
that doctor responses may have been influenced 
by the many years of definitions of hyperuricemia, 
which have differed significantly between publica-
tions, i.e. epidemiological studies were inconsist-
ent. Hyperuricemia used to be considered present 
when uric acid concentration in blood serum 
exceeded 7 mg/dL in male patients and 6 mg/dL 
in female patients. According to another defini-
tion hyperuricemia was defined as values above 
6.4–6.8 mg/dL, at 37°C, being the total saturation 
of the plasma with sodium urate takes place [11]. 
Therefore, it still seems necessary to educate the 
medical community with regards to the definition 
of the value of hyperuricemia in patients with high 
cardiovascular risk.
Uric acid is recognized as an independent risk 
factor in the development of many macrovascular 
and microvascular disorders, including arterial hy-
pertension [12], metabolic syndrome [13, 14], CAD 
[15], diabetes [16], cerebrovascular disease [17, 18], 
CKD [19] or other CVD [20, 21]. When asked what 
diseases, in their opinion, are most often associated 
with hyperuricemia, the respondents listed the fol-
lowing: hypertension (91%), metabolic syndrome 
(89%) and diabetes (84%). An increased concentra-
tion of uric acid impairs oxygen metabolism, stimu-
lates the renin–angiotensin system and inhibits the 
secretion of endothelial nitric oxide. Therefore, it 
contributes to the development of microvascular 
complications in arterioles vasoconstriction, renal 
vasoconstriction, and persistent sodium chloride hy-
pertension [22, 23]. As evidenced, most physicians 
are aware of the relationship between the increase 
in a relative risk of hypertension and high levels of 
uric acid [24, 25]. Most also know the relationship 
between hyperuricemia and metabolic syndrome. 
Diabetes as a disease often accompanying hyperuri-
cemia is also indicated much less frequently — by 
8 out of 10 doctors. It seems that respondents have 
the knowledge that elevated uric acid is the result 
of a diet which is rich in purine/fructose, genetic and 
environmental factors, metabolic disorders as well 
as endogenous overproduction or, in most cases, im-
paired excretion of uric acid. Pre-clinical test results 
suggest that endothelial dysfunction, inflammatory 
reaction and oxidative stress in fat cells play a key role 
in the development of metabolic syndrome [26]. Some 
studies describe the relationship between uricemia 
and obesity, between uricemia and obesity and insulin 
resistance. Therefore, uric acid was suggested as 
a component of the metabolic syndrome [27]. 
Yet, what was surprising was the lack of aware-
ness of the doctors surveyed, of the relationship be-
tween hyperuricaemia and ischemic heart disease, 
and thus a growing cardiovascular risk. Oxidative 
stress caused by increased xanthine oxidase activ-
ity has a very negative effect on the endothelium 
vascular system, including coronary arteries [28, 
29]. Based on data from the NHANES I study (First 
National Health and Nutrition Examination Study), 
Freedman et al. [1] proved that any increase in the 
value of uric acid concentration by 60 μmol/L is 
linked with a 48% increase in the risk of ischemic 
heart disease in women. In patients demonstrating 
cardiovascular complications (with angiographi-
cally diagnosed CAD, after ischemic stroke, with 
chronic heart failure) it has been shown that uric 
acid concentration is an independent prognostic 
factor for general and cardiovascular mortality of 
patients [30–32].
Moreover, the surveyed doctors do not men-
tion the correlation of hyperuricemia with CKD, 
and high levels of uric acid, which indeed play a key 
role in the development and progression of CKD. It 
also remains an independent factor in the progres-
sion of CKD, even after adjustment for all classical 
co-existing diseases, such as hypertension, pro-
teinuria and dyslipidaemia. This relationship was 
confirmed in patients with IgA nephropathy, dia-
betic nephropathy, after organ transplantation and 
in autosomal dominant polycystic kidney disease. 
Almost 1/3 of physicians declared that the 
average age of their patients with hyperuricemia 
> 5 mg/dL (298 μmol/L) in the cardiovascular 
risk group was 50 years or less, and another 1/3 
declared that their age was 60 years or more. The 
prevalence hyperuricemia depends on the sex, age 
and race and reaches its peak in people at around 
the age of 70. In young and healthy people, before 
puberty, it is low and usually does not exceed 
3.6 mg/dL. In men, it is on average 5 ± 2 mg/dL, 
and in women at childbearing age it is on average 
1 mg/dL lower, and increases after menopause (the 
role of oestrogen). Yet, it should be remembered 
that the elevated concentration of uric acid is ob-
served in almost 90% of adolescents with primary 
hypertension [33].
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Almost half of physicians in the present 
study check serum uric acid concentration once 
a year in patients with hyperuricemia > 5 mg/dL 
(298 μmol/L) in the cardiovascular risk group 
and 38% of physicians will order the test for their 
patients twice a year. In patients in whom are 
introduced a hyperendemic agent, urine acid con-
centration should be controlled every 4 weeks after 
each increase of the dose until a therapeutic goal is 
achieved. According to the recommendations, after 
a therapeutic goal is achieved the dose of a drug 
reducing uric acid concentration (in practice, allopu-
rinol) should be maintained, and uric acid concentra-
tion should be monitored periodically, twice a year.
The vast majority of doctors, namely 3/4 of 
respondents start pharmacological treatment of 
hyperuricemia in patients at risk of CVD only when 
the concentration of uric acid is between 6 and 
7 mg/dL, 14% — when the concentration is lower 
than 6 mg/dL, and another 11% — when it is above 
7 mg/dL. Once again one should be reminded that 
based on the current knowledge of physicians, 
they consider treatment with allopurinol when the 
level of uric acid is above 5 mg/dL in patients with 
high cardiovascular risk, presenting at least two of 
the following conditions: hypertension, diabetes, 
dyslipidaemia, recent stroke or myocardial infarc-
tion or CKD.
The international consensus on hyperuricemia 
in patients with high cardiovascular risk suggests 
that physicians should consider administering 
an initial dose of allopurinol of 100 mg daily, and 
gradually increase it to 300–600 mg per day, until 
the target concentration of uric acid is reached 
[9, 34]. A slow increase in the dose of allopurinol 
has resulted from the need to minimize the likeli-
hood of an incidence of side effects, especially 
in patients with hypersensitivity to allopurinol 
or severe cutaneous allergic reactions (SCARs), 
which usually occurs after 8 weeks of the treatment 
[35–37]. There are several factors that especially 
contributed to the development of this syndrome, 
such as high initial doses, CKD, parallel use of diu-
retics or the presence of HLA-B*5801 [38, 39]. Al-
most all doctors surveyed in the study declared that 
they increased doses of uric acid-lowering drugs in 
patients with hyperuricemia in the cardiovascular 
risk group — only 2% of physicians over the prior 
3–4 months did not have such patients. The aver-
age percentage of patients with hyperuricemia from 
the cardiovascular risk groups in which doctors 
increase the dose of medicine lowering uric acid 
levels is 23% (taking into account only doctors who 
increase the dose).
Allopurinol therapy in patients with high car-
diovascular risk is a chronic treatment. 90% of the 
respondents gave such a response. Nearly 80% of 
physicians believe that hyperuricemia (> 5 mg/dL, 
298 μmol/L) considerably affects cardiovascular risk. 
The remaining 20% of doctors believe that the impact 
of hyperuricemia on cardiovascular risk is moderate. 
Hyperuricemia plays an important pathophysiological 
role in the development of hypertension, type 2 dia-
betes and is an independent cardiovascular risk factor.
Important data confirming the predictive value 
of uric acid concentrations were obtained based 
from observations of the original Framingham 
heart study cohort. Thus, the study showed an 
increased risk of ischemic disease and myocardial 
infarction in patients with high levels of uric acid 
in serum. Krishnan et al. [40] confirmed the in-
dependent effect of uric acid on the risk of acute 
myocardial infarction. In the Rotterdam Study 
(n = 4385) in patients without a history of myo-
cardial infarction or stroke at the beginning of the 
study, high uric acid concentrations were associ-
ated with a distant risk of myocardial infarction and 
stroke [41]. In a study by Ndrepepa et al. [42] the 
total of 5124 patients with acute coronary syndromes 
(1629 myocardial infarction with ST segment eleva-
tion, 1332 myocardial infarction without ST segment 
elevation and 2163 with unstable angina) were divided 
into quartiles according to uric acid concentration 
levels as follows: quartile 1: 1.3–5.3 mg/dL (77–315 
μmol/L); quartile 2: 5.3–6.3 mg/dL (315–375 μmol/L); 
quartile 3: 6.3–7.5 mg/dL (375–446 μmol/L); quartile 
4: 7.5–18.4 mg/dL (446–1094 μmol/L). After 1 year 
of observations there were 80 deaths in quartile 1, 
77 deaths in quartile 2, 72 deaths in quartile 3, and 
221 deaths in the quartile 4 of uric acid concentra-
tions. The unadjusted mortality risk ratio was 3.05 
(95% confidence interval 2.54–3.67, p < 0.001) for 
the quartile 4 vs. quartile 1 of these concentrations. 
It should be noted that after taking into account the 
traditional cardiovascular risk factors, renal functions 
and inflammation, the relationship between uric acid 
concentration and mortality remained significant.
91% of the physicians surveyed had seen an 
increase in the incidence of hyperuricemia in pa-
tients at risk of CVD over the prior 2 years. The 
trend observed by doctors is correct. In the coming 
years, due to the epidemic of obesity, metabolic 
disorders and an aging population, the incidence 
of hyperuricemia will continue to be observed. It 
is also related to rapid economic development and 
a changing lifestyle of societies which enjoy 
a higher social and economic status. Rising uric acid 
levels also result from the adoption of a Western 
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lifestyle and changing economic status. Increased 
morbidity from hyperuricemia is also favoured by 
such commonly adopted habits as excessive con-
sumption of products rich in purines (meat, offal), 
fructose, glucose and fructose syrup or alcohol.
Conclusions
The findings of the questionnaire in the pre-
sent survey suggest that doctors often underes-
timate the problem of hyperuricemia in patients 
with high risk of CVD. An important step towards 
more effective therapy of hyperuricemia in routine 
clinical practice will be to raise the awareness of 
hyperuricemia and comorbidities both among doc-
tors and patients and encourage their monitoring 
and treatment. Patients should be educated on the 
impact some foods on the development of uricemia: 
high consumption red meat and seafood, alcohol, 
fructose and sweetened beverages. Research has 
also confirmed that weight loss and regular physical 
activity should be highly recommended.
The dissemination of information about the new 
norm for uricemia in high-risk cardiovascular patients 
was largely supported by the introduction of an appro-
priate legend containing information about standards 
for different patient populations in the results of tests 
conducted by the majority of large medical laboratories. 
Introduction of explanatory information, as was previ-
ously the case in the lipid profile (different purpose 
of therapy depending on cardiovascular risk), will 
certainly help to raise awareness of hyperuricemia 
in cardiac patients and achieving  therapeutic goals.
Allopurinol should be the first-line treatment 
of hyperuricemia. An initial dose of 100 mg of al-
lopurinol daily should be considered. The dose 
should gradually be increased to 300–600 mg per 
day until reaching the goal conforming to the target 
uric acid concentration. In cases where a therapeu-
tic goal cannot be achieved; the treatment should 
be changed to a more complex therapy.
The international consensus on the treatment 
of patients with hyperuricemia and high cardio-
vascular risk, suggests a simple 5-step scheme 
(Fig. 11 [9]). This scheme should considered a sort 
of road map for doctors in the treatment of patients 
with high cardiovascular risk with co-occurring 
hyperuricemia.
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